Evidence map›Paper›PMID 36262287›Full record

ArticleHeliyon2022

One-pot multi-functional finishing of wool fabric using reactive nonionic softener.

H El-Sayed, S Mowafi, A S Basuoni

Abstract read
In one paragraph

Article in Heliyon, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

H El-SayedProteinic and Man-made Fibres Department, Textile Research and Technology Institute, National Research Centre, 12622-Dokki, Giza, Egypt.
S MowafiProteinic and Man-made Fibres Department, Textile Research and Technology Institute, National Research Centre, 12622-Dokki, Giza, Egypt.
A S BasuoniProteinic and Man-made Fibres Department, Textile Research and Technology Institute, National Research Centre, 12622-Dokki, Giza, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Crossbred wool is widely used in the textile and clothing fields. Nevertheless, the surface roughness of crossbred wool fabric is higher than that of Merino wool. Herein we propose a reactive nonionic softener (RNS) based on fatty acid (FA) and 2-amino-2-methyl propane diol (AMPD) to impart desirable multi-functions for crossbred wool fabric, such as improved smoothness, enhanced wettability, and induced resistance to felting shrinkage. Adopting the pad-dry-cure method, treatment of wool with the said softener was carried out using different concentrations of FA/AMPD condensate at different curing temperatures and durations. The results showed that the highest fabric surface smoothness was attained when wool fabric was treated with 3.5% (o.w.f.) RNS, and the curing temperature and time were 130 °C and 5 min, respectively. The surface smoothness of the treated fabric and its resistance to felting shrinkage were increased by 21.7% and 90% respectively. The effects of treatment of wool with the RNS on its bending stiffness, air and water permeability, yellowness, electrostatic charge, and ultraviolet protection factor (UPF) were monitored. The reaction mechanism between the used RNS and wool was studied using FTIR spectroscopy. Scanning electron microscopic investigation showed a layer of the used RNS on the surface of the treated fabric. The finished fabric retained its air permeability and dyeability with anionic dye. The imparted fabric smoothness was find to be durable against washing until 5 washing cycles, and decreased by 5.5% of after 10 washing cycles respectively.

Indexed as

FabricFelting shrinkageNonionic softenerSmoothnessWool

Identifiers

PMID36262287
PMCPMC9573922

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.